Cutaneous side-effects of kinase inhibitors and blocking antibodies

Caroline Robert, Jean Charles Soria, Alain Spatz, Axel Le Cesne, David Malka, Patricia Pautier, Janine Wechsler, Catherine Lhomme, Bernard Escudier, Valérie Boige, Jean Pierre Armand, Thierry Le Chevalier

Research output: Contribution to journalReview articlepeer-review

491 Scopus citations


Although kinase inhibitors raise hope for people with cancer, patients and their clinicians are commonly confronted with the cutaneous side-effects that are associated with the use of these drugs. This review is the result of collaborations between dermatologists, medical oncologists, and pathologists, and discusses the cutaneous side-effects seen after treatment with the inhibitors of epidermal-growth-factor receptor (EGFR), imatinib, sorafenib, and sunitinib. Some of the side-effects caused by these agents are very distressing, partly because they are chronic owing to the long duration of treatment. Therefore, patients need early and appropriate dermatological management. Moreover, several studies have reported a link between the antitumour efficacy of EGFR inhibitors and cutaneous side-effects. Elucidation of this connection could lead to the identification of crucial predictive factors for tumour response.

Original languageEnglish
Pages (from-to)491-500
Number of pages10
JournalThe Lancet Oncology
Issue number7
StatePublished - Jul 2005
Externally publishedYes


Dive into the research topics of 'Cutaneous side-effects of kinase inhibitors and blocking antibodies'. Together they form a unique fingerprint.

Cite this